JP2004530649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004530649A5 JP2004530649A5 JP2002562710A JP2002562710A JP2004530649A5 JP 2004530649 A5 JP2004530649 A5 JP 2004530649A5 JP 2002562710 A JP2002562710 A JP 2002562710A JP 2002562710 A JP2002562710 A JP 2002562710A JP 2004530649 A5 JP2004530649 A5 JP 2004530649A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- prodrug
- pharmaceutically acceptable
- stereoisomer
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 136
- 229940002612 prodrug Drugs 0.000 claims 86
- 239000000651 prodrug Substances 0.000 claims 86
- 150000003839 salts Chemical class 0.000 claims 43
- 239000012453 solvate Substances 0.000 claims 43
- 239000000203 mixture Substances 0.000 claims 24
- 239000003018 immunosuppressive agent Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 150000003431 steroids Chemical class 0.000 claims 16
- 229960003444 immunosuppressant agent Drugs 0.000 claims 12
- -1 haloC 1 -C 6 alkyl Chemical group 0.000 claims 10
- 201000006417 multiple sclerosis Diseases 0.000 claims 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 10
- 201000004681 Psoriasis Diseases 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 8
- 108010036949 Cyclosporine Proteins 0.000 claims 8
- 108010008165 Etanercept Proteins 0.000 claims 8
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 8
- 239000000460 chlorine Substances 0.000 claims 8
- 229960001265 ciclosporin Drugs 0.000 claims 8
- 229940111134 coxibs Drugs 0.000 claims 8
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims 8
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 8
- 229930182912 cyclosporin Natural products 0.000 claims 8
- 229940073621 enbrel Drugs 0.000 claims 8
- 230000001861 immunosuppressant effect Effects 0.000 claims 8
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 8
- 229960000681 leflunomide Drugs 0.000 claims 8
- 229960000485 methotrexate Drugs 0.000 claims 8
- 229940116176 remicade Drugs 0.000 claims 8
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 8
- 229960001940 sulfasalazine Drugs 0.000 claims 8
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 8
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 4
- 108010005716 Interferon beta-1a Proteins 0.000 claims 4
- 108010005714 Interferon beta-1b Proteins 0.000 claims 4
- 229940003504 avonex Drugs 0.000 claims 4
- 229940021459 betaseron Drugs 0.000 claims 4
- 229940047495 celebrex Drugs 0.000 claims 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical group C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 4
- 229940038717 copaxone Drugs 0.000 claims 4
- 229940065410 feldene Drugs 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229940124589 immunosuppressive drug Drugs 0.000 claims 4
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical group OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 4
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 4
- 229940087652 vioxx Drugs 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 229960002537 betamethasone Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000000884 Airway Obstruction Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26737501P | 2001-02-08 | 2001-02-08 | |
| US29260001P | 2001-05-22 | 2001-05-22 | |
| PCT/US2002/003672 WO2002062750A1 (en) | 2001-02-08 | 2002-02-07 | Cannabinoid receptor ligands |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008186568A Division JP2009024011A (ja) | 2001-02-08 | 2008-07-17 | カンナビノイドレセプターリガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004530649A JP2004530649A (ja) | 2004-10-07 |
| JP2004530649A5 true JP2004530649A5 (enExample) | 2005-12-22 |
| JP4330341B2 JP4330341B2 (ja) | 2009-09-16 |
Family
ID=26952402
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002562710A Expired - Fee Related JP4330341B2 (ja) | 2001-02-08 | 2002-02-07 | カンナビノイドレセプターリガンド |
| JP2008186568A Withdrawn JP2009024011A (ja) | 2001-02-08 | 2008-07-17 | カンナビノイドレセプターリガンド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008186568A Withdrawn JP2009024011A (ja) | 2001-02-08 | 2008-07-17 | カンナビノイドレセプターリガンド |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7507767B2 (enExample) |
| EP (1) | EP1368308A1 (enExample) |
| JP (2) | JP4330341B2 (enExample) |
| KR (1) | KR20030075175A (enExample) |
| CN (1) | CN1285572C (enExample) |
| AR (1) | AR032569A1 (enExample) |
| AU (1) | AU2002306450B2 (enExample) |
| BR (1) | BR0206955A (enExample) |
| CA (1) | CA2436659C (enExample) |
| CZ (1) | CZ20032122A3 (enExample) |
| HU (1) | HUP0304060A3 (enExample) |
| IL (1) | IL156829A0 (enExample) |
| MX (1) | MXPA03007078A (enExample) |
| NO (1) | NO20033505L (enExample) |
| NZ (1) | NZ526782A (enExample) |
| PE (1) | PE20020851A1 (enExample) |
| PL (1) | PL364624A1 (enExample) |
| RU (1) | RU2003127368A (enExample) |
| SK (1) | SK9952003A3 (enExample) |
| WO (1) | WO2002062750A1 (enExample) |
| ZA (1) | ZA200305933B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
| BR0212510A (pt) * | 2001-09-14 | 2004-08-24 | Methylgene Inc | Inibidor de histona desacetilase, composto e composição |
| US6897220B2 (en) * | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US7868204B2 (en) * | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| BR0214164A (pt) | 2001-11-14 | 2004-09-28 | Schering Corp | Ligantes do receptor canabinóide |
| WO2003061699A1 (en) * | 2001-12-27 | 2003-07-31 | Japan Tobacco, Inc. | Remedies for allergic diseases |
| CA2478338A1 (en) | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| ES2303599T3 (es) | 2002-06-19 | 2008-08-16 | Schering Corporation | Agonistas de los receptores de cannabinoides. |
| UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| MY140236A (en) * | 2002-09-19 | 2009-12-31 | Lilly Co Eli | Diarylether compounds useful as opioid receptor antagonists |
| GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| GB0222495D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| AU2003268926B2 (en) | 2002-10-24 | 2010-06-17 | Merck Patent Gmbh | Methylene urea derivatives as raf-kinase inhibitors |
| AU2003294449A1 (en) * | 2002-11-25 | 2004-06-18 | Schering Corporation | Cannabinoid receptor ligands |
| US20060172019A1 (en) * | 2003-03-07 | 2006-08-03 | Ralston Stuart H | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| US6916852B2 (en) * | 2003-05-12 | 2005-07-12 | University Of Tennessee Research Foundation | Method for regulation of microvascular tone |
| WO2004113320A1 (en) * | 2003-05-20 | 2004-12-29 | The University Of Tennessee Research Foundation | Cannabinoid derivatives, methods of making, and use thereof |
| JP4809228B2 (ja) * | 2003-09-24 | 2011-11-09 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| US7320805B2 (en) * | 2003-10-01 | 2008-01-22 | Institut National De La Sante Et De La Recherche Medicale | CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver |
| US7390835B2 (en) * | 2003-10-30 | 2008-06-24 | Merck & Co., Inc. | Aralkyl amines as cannabinoid receptor modulators |
| GB0402357D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| GB0402355D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| US7253204B2 (en) * | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| DE602005024838D1 (en) | 2004-09-30 | 2010-12-30 | Merck Sharp & Dohme | Cyclopropylpiperidinglycin-transporter-inhibitor |
| CA2632030A1 (en) | 2005-12-15 | 2007-06-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| WO2007118137A1 (en) * | 2006-04-07 | 2007-10-18 | Methylgene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
| JP5448164B2 (ja) | 2006-07-28 | 2014-03-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を変調する化合物 |
| AU2007297285A1 (en) * | 2006-09-08 | 2008-03-20 | Pfizer Products Inc. | Diaryl ether derivatives and uses thereof |
| EP2074084B1 (en) | 2006-09-25 | 2013-08-28 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
| GB0702862D0 (en) * | 2007-02-14 | 2007-03-28 | Univ Aberdeen | Therapeutic compounds |
| RU2011116111A (ru) | 2008-09-25 | 2012-10-27 | Бёрингер Ингельхайм Интернациональ Гмбх (De) | Сульфонилсодержащие соединения, которые селективно модулируют рецептор св2 |
| CA2765044A1 (en) | 2009-06-09 | 2010-12-16 | California Capital Equity, Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
| ES2557453T3 (es) | 2009-06-09 | 2016-01-26 | Nantbioscience, Inc. | Derivados de isoquinolina, quinolina y quinazolina como inhibidores de la señalización de Hedgehog |
| CA2765030C (en) | 2009-06-09 | 2015-10-27 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
| WO2011088015A1 (en) | 2010-01-15 | 2011-07-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| EP2595959B1 (en) | 2010-07-22 | 2015-11-04 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
| US20120309820A1 (en) * | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| TW201329025A (zh) | 2011-11-01 | 2013-07-16 | Astex Therapeutics Ltd | 醫藥化合物 |
| KR101599300B1 (ko) * | 2012-03-14 | 2016-03-03 | 시노켐 코포레이션 | 치환 디페닐아민 화합물 및 항종양제로서의 용도 |
| WO2014127016A2 (en) | 2013-02-12 | 2014-08-21 | Jb Therapeutics, Inc. | Ultrapure tetrahydrocannabinol-11-oic acids |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| CN103265480B (zh) * | 2013-05-11 | 2015-10-07 | 浙江大学 | 喹啉二酮类衍生物及其制备方法和用途 |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| US9636298B2 (en) | 2014-01-17 | 2017-05-02 | Methylgene Inc. | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| ES2901114T3 (es) | 2014-08-29 | 2022-03-21 | Tes Pharma S R L | Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa |
| CN108752375A (zh) * | 2018-07-17 | 2018-11-06 | 成都睿智化学研究有限公司 | 一种4-溴甲基-2-三甲基硅乙炔基苯-1-磺酰氟的制备方法 |
| EP3986882A4 (en) | 2019-06-24 | 2023-04-05 | Diverse Biotech, Inc. | BETA-LACTAM CANNABINOID CONJUGATE MOLECULE |
| CN112552200B (zh) * | 2019-09-10 | 2024-03-12 | 烟台药物研究所 | 一种光学纯4-(1-氨基)乙基苯甲酸酯及其盐的制备方法 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3715375A (en) * | 1970-09-17 | 1973-02-06 | Merck & Co Inc | New diphenyl sulfones |
| US3712888A (en) * | 1970-12-14 | 1973-01-23 | American Cyanamid Co | Bis-pyridoxazole-stilbene derivatives for optical brightening |
| US4170648A (en) | 1972-05-26 | 1979-10-09 | Rohm And Haas Company | Phosphonothioureide anthelmintics |
| DE3039208A1 (de) | 1980-10-17 | 1982-05-13 | Basf Ag, 6700 Ludwigshafen | Neue sulfone, deren herstellung und verwendung |
| DE3118126A1 (de) | 1981-05-07 | 1982-12-02 | Bayer Ag, 5090 Leverkusen | Sulfenamide zur verwendung in arzneimitteln |
| US4618363A (en) | 1982-01-25 | 1986-10-21 | Ciba-Geigy Corporation | N-phenylsulfonyl-N'-triazinylureas |
| US4468389A (en) | 1982-05-21 | 1984-08-28 | Rohm And Haas Company | Pesticidal N-sulfonyl phosphorodiamido(di)thioates |
| US4466965A (en) | 1982-07-26 | 1984-08-21 | American Hospital Supply Corporation | Phthalazine compounds, compositions and use |
| US4468965A (en) * | 1982-11-05 | 1984-09-04 | Union Carbide Corporation | Test method for acetylene cylinders |
| US4567184A (en) | 1982-12-01 | 1986-01-28 | Usv Pharmaceutical Corporation | Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies |
| NZ213986A (en) | 1984-10-30 | 1989-07-27 | Usv Pharma Corp | Heterocyclic or aromatic compounds, and pharmaceutical compositions containing such |
| US4764889A (en) | 1984-12-19 | 1988-08-16 | American Telephone And Telegraph Company, At&T Bell Laboratories | Optical logic arrangement with self electro-optic effect devices |
| US4781866A (en) | 1985-03-15 | 1988-11-01 | Mcneilab, Inc. | Process for producing amidine sulfonic acid intermediates for guanidines |
| US4678855A (en) | 1985-10-09 | 1987-07-07 | Merck & Co., Inc. | Substituted benzenesulfonamides |
| WO1987005781A2 (en) | 1986-03-31 | 1987-10-08 | Rhone-Poulenc Nederlands B.V. | Synergistic plant growth regulator compositions |
| CA1340056C (en) | 1986-03-31 | 1998-09-22 | David Treadway Manning | Use of malonic acid derivative compounds for retarding plant growth |
| DE3634926A1 (de) | 1986-10-14 | 1988-04-21 | Bayer Ag | Verfahren zur herstellung von o-aryl-n'-pyrimidin-2-yl-isoharnstoffen |
| DE3634927A1 (de) | 1986-10-14 | 1988-04-21 | Bayer Ag | Verfahren zur herstellung von sulfonylisothioharnstoffen |
| US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
| CA1293516C (en) | 1987-02-10 | 1991-12-24 | Izumi Fujimoto | Benzoylurea derivative and its production and use |
| NZ232493A (en) | 1989-02-14 | 1992-06-25 | Toyama Chemical Co Ltd | Aryl- or heterocyclyl-substituted 1,2-ethanediol derivatives and pharmaceutical compositions |
| US5064825A (en) | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
| KR920701167A (ko) | 1989-07-07 | 1992-08-11 | 에릭 에스. 딕커 | 약제학적 활성 화합물 |
| IT1240676B (it) | 1990-04-24 | 1993-12-17 | Agrimont Spa | Composizioni ad attivita' erbicida |
| NZ239846A (en) | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
| US5332820A (en) | 1991-05-20 | 1994-07-26 | E. I. Du Pont De Nemours And Company | Dibenzobicyclo(2.2.2) octane angiotensin II antagonists |
| PT100639A (pt) | 1991-06-27 | 1993-09-30 | Univ Virginia Commonwealth | Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina |
| US5506227A (en) | 1992-04-13 | 1996-04-09 | Merck Frosst Canada, Inc. | Pyridine-substituted benzyl alcohols as leukotriene antagonists |
| US5338753A (en) | 1992-07-14 | 1994-08-16 | Sumner H. Burstein | (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics |
| GB9218834D0 (en) | 1992-09-05 | 1992-10-21 | Procter & Gamble | Nasal spray products |
| AU7100394A (en) | 1993-06-17 | 1995-01-17 | Dunlena Pty. Limited | Arthropodicidal sulfonates |
| US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| US5948819A (en) | 1994-04-06 | 1999-09-07 | Shionogi & Co., Ltd | α-substituted phenylacetic acid derivative, its production and agricultural fungicide containing it |
| IT1271266B (it) * | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
| ES2151652T3 (es) | 1995-02-02 | 2001-01-01 | Smithkline Beecham Plc | Derivados de indol como antagonistas del receptor 5ht. |
| US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| US5700816A (en) | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| PT848703E (pt) | 1995-07-21 | 2001-01-31 | Nycomed Austria Gmbh | Derivados de benzosulfonamidas como inibidores da enzima ciclo-oxigenase ii |
| DE19533644A1 (de) | 1995-09-12 | 1997-03-13 | Nycomed Arzneimittel Gmbh | Neue Benzolsulfonamide |
| FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| EP0887340A4 (en) | 1996-02-06 | 2000-03-29 | Japan Tobacco Inc | CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE |
| SE9602646D0 (sv) | 1996-07-04 | 1996-07-04 | Astra Ab | Pharmaceutically-useful compounds |
| EP0927035A4 (en) | 1996-09-13 | 2002-11-13 | Merck & Co Inc | THROMBIN INHIBITORS |
| JP3426890B2 (ja) | 1996-12-25 | 2003-07-14 | アルプス電気株式会社 | 入力ペン |
| ES2213892T3 (es) | 1997-01-21 | 2004-09-01 | Smithkline Beecham Corporation | Nuevos moduladores del receptor de canabinoides. |
| ATA16597A (de) | 1997-02-03 | 1998-04-15 | Nycomed Austria Gmbh | Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide |
| DE19740785A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Arylsulfonamide und Analoga |
| TR199902012T2 (xx) | 1997-02-21 | 2000-01-21 | Bayer Aktiengesellschaft | Arils�lfonamidler ve analoglar� |
| CA2283797A1 (en) | 1997-03-18 | 1998-09-24 | Paul Elliot Bender | Novel cannabinoid receptor agonists |
| DE69842143D1 (de) | 1997-10-24 | 2011-04-07 | Nissan Chemical Ind Ltd | Sulfamoyl-verbindungen und bakterizide für landwirtschaft oder gartenbau |
| WO1999026612A1 (en) | 1997-11-21 | 1999-06-03 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
| HUP0103460A3 (en) | 1998-03-26 | 2002-11-28 | Shionogi & Co | Indole derivatives with antiviral activity and pharmaceutical compositions containing them |
| CN1310621A (zh) | 1998-07-28 | 2001-08-29 | 史密丝克莱恩比彻姆公司 | 取代的n－酰苯胺化合物和方法 |
| JP2000143650A (ja) | 1998-11-13 | 2000-05-26 | Takeda Chem Ind Ltd | 新規チアゾリジン誘導体、その製造法および用途 |
| AU3772800A (en) | 1999-03-24 | 2000-10-09 | Sepracor, Inc. | Diaryl thioethers, compositions and uses thereof |
| JP4618845B2 (ja) | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体 |
| WO2001014351A1 (en) * | 1999-08-23 | 2001-03-01 | Kyorin Pharmaceutical Co., Ltd. | Substituted benzylthiazolidine-2,4-dione derivatives |
| US6818640B1 (en) | 1999-09-14 | 2004-11-16 | Shionogi & Co., Ltd. | 2-imino-1,3-thiazine derivatives |
| AU1095101A (en) | 1999-10-18 | 2001-04-30 | University Of Connecticut, The | Cannabimimetic indole derivatives |
| CN1391469B (zh) | 1999-11-26 | 2010-05-26 | 盐野义制药株式会社 | Npy y5拮抗剂 |
| CA2395088A1 (en) | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| US20020052343A1 (en) | 1999-12-15 | 2002-05-02 | Allen Darin Arthur | Salicylamides as serine protease inhibitors |
| US6952871B1 (en) | 1999-12-31 | 2005-10-11 | Lear Automotive (Eeds) Spain, S.L. | Method for manufacturing printed circuit boards |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| JP2003528107A (ja) | 2000-03-22 | 2003-09-24 | メルク フロスト カナダ アンド カンパニー | Ｐｔｐ−１ｂ阻害薬としての硫黄置換アリールジフルオロメチルホスホン酸類 |
| WO2001074762A2 (en) | 2000-04-03 | 2001-10-11 | Phycogen, Inc. | Arylsulfates and their use as enhancers or inhibitors of bioadhesion to surfaces |
| US20040110743A1 (en) | 2000-05-19 | 2004-06-10 | Masaomi Miyamato | -Secretase inhibitors |
| GB0028702D0 (en) | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
| US7067539B2 (en) * | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
| BR0214164A (pt) | 2001-11-14 | 2004-09-28 | Schering Corp | Ligantes do receptor canabinóide |
-
2002
- 2002-02-06 US US10/072,354 patent/US7507767B2/en not_active Expired - Fee Related
- 2002-02-07 JP JP2002562710A patent/JP4330341B2/ja not_active Expired - Fee Related
- 2002-02-07 CN CNB028043081A patent/CN1285572C/zh not_active Expired - Fee Related
- 2002-02-07 MX MXPA03007078A patent/MXPA03007078A/es active IP Right Grant
- 2002-02-07 CA CA2436659A patent/CA2436659C/en not_active Expired - Fee Related
- 2002-02-07 WO PCT/US2002/003672 patent/WO2002062750A1/en not_active Ceased
- 2002-02-07 SK SK995-2003A patent/SK9952003A3/sk unknown
- 2002-02-07 AU AU2002306450A patent/AU2002306450B2/en not_active Ceased
- 2002-02-07 NZ NZ526782A patent/NZ526782A/en unknown
- 2002-02-07 PL PL02364624A patent/PL364624A1/xx not_active Application Discontinuation
- 2002-02-07 BR BR0206955-5A patent/BR0206955A/pt not_active IP Right Cessation
- 2002-02-07 KR KR10-2003-7010270A patent/KR20030075175A/ko not_active Ceased
- 2002-02-07 RU RU2003127368/04A patent/RU2003127368A/ru not_active Application Discontinuation
- 2002-02-07 HU HU0304060A patent/HUP0304060A3/hu unknown
- 2002-02-07 EP EP02740074A patent/EP1368308A1/en not_active Withdrawn
- 2002-02-07 CZ CZ20032122A patent/CZ20032122A3/cs unknown
- 2002-02-07 IL IL15682902A patent/IL156829A0/xx unknown
- 2002-02-08 AR ARP020100423A patent/AR032569A1/es unknown
- 2002-02-08 PE PE2002000095A patent/PE20020851A1/es not_active Application Discontinuation
-
2003
- 2003-07-31 ZA ZA2003/05933A patent/ZA200305933B/en unknown
- 2003-08-07 NO NO20033505A patent/NO20033505L/no not_active Application Discontinuation
-
2005
- 2005-08-15 US US11/203,946 patent/US7718702B2/en not_active Expired - Fee Related
-
2008
- 2008-07-17 JP JP2008186568A patent/JP2009024011A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004530649A5 (enExample) | ||
| JP2005534715A5 (enExample) | ||
| CA2436659A1 (en) | Cannabinoid receptor ligands | |
| EP3768667B1 (en) | Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses | |
| JP2017505808A5 (enExample) | ||
| JP6218260B2 (ja) | Ｊａｋ阻害剤としてのアミノピリミジニル化合物 | |
| CN110475775B (zh) | 4-吡啶酮化合物或其盐、包含4-吡啶酮化合物的药物组合物及剂 | |
| RU2014106020A (ru) | Ингибиторы втк | |
| CN100496493C (zh) | 2-氨基-4,5-三取代噻唑基衍生物 | |
| JP2017501234A5 (enExample) | ||
| JP2017510644A5 (enExample) | ||
| AR040803A1 (es) | Ligandos de receptores canabinoides, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o combinados, para la preparacion de medicamentos | |
| JP2018534326A5 (enExample) | ||
| JP2017510643A5 (enExample) | ||
| CA2709786A1 (en) | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | |
| JP2017510642A5 (enExample) | ||
| JP2017531000A5 (enExample) | ||
| RU2004117907A (ru) | Лиганды каннабиноидных рецепторов | |
| JP2009534407A5 (enExample) | ||
| RU2014131378A (ru) | Ингибиторы бромдомена | |
| JP2016522246A5 (enExample) | ||
| JP2008503585A5 (enExample) | ||
| CA2671982A1 (en) | Methods of using mek inhibitors | |
| JP2015529224A5 (enExample) | ||
| JP2018515438A5 (enExample) |